Search
EHA Guidelines by Topic
AL Amyloidosis
Guidelines for high dose chemotherapy and stem cell transplantation for systemic AL amyloidosis: EHA-ISA working group guidelines (2021)
Guidelines for non-transplant chemotherapy for treatment of systemic AL amyloidosis: EHA-ISA working group (2022)
Anemia
Recommendations regarding splenectomy in hereditary hemolytic anemias (2017)
Management of…
The EHA Guidelines Workshop, a meaningful and successful first Series!
November 2020 – April 2021
In the past six months, hematologists, clinicians, transfusion medicine specialists, oncologists, special nurses and researchers gathered virtually for the first EHA Guidelines Workshop series.
Other COVID-19 Resources
Safety of COVID-19 vaccines – April updates
ECDC and EMA issue advice on fourth doses of mRNA COVID-19 vaccines
EMA recommends authorisation of COVID-19 medicine Evusheld
EMA recommends authorisation of booster doses of Comirnaty from 12 years of age
EMA recommends approval of Spikevax…
Sickle Cell Disease: From Research to Clinical Management
Elevate your expertise and impact patient care by joining the EHA's pilot preceptorship on Sickle Cell Disease, designed for early-career hematology specialists, clinicians, lab technicians, and pathologists.
Read more- «
- 1
- 2
- 3
- 4
- 5
- 6
- 7
- 8
- 9
- 10
- 11
- 12
- 13
- 14
- 15
- 16
- 17
- 18
- 19
- 20
- 21
- 22
- 23
- 24
- 25
- 26
- 27
- 28
- 29
- 30
- 31
- 32
- 33
- 34
- 35
- 36
- 37
- 38
- 39
- 40
- 41
- 42
- 43
- 44
- 45
- 46
- 47
- 48
- 49
- 50
- 51
- 52
- 53
- 54
- 55
- 56
- 57
- 58
- 59
- 60
- 61
- 62
- 63
- 64
- 65
- 66
- 67
- 68
- 69
- 70
- 71
- 72
- 73
- 74
- 75
- 76
- 77
- 78
- 79
- 80
- 81
- 82
- 83
- 84
- 85
- 86
- 87
- 88
- 89
- 90
- 91
- 92
- 93
- 94
- 95
- 96
- 97
- 98
- 99
- 100
- 101
- 102
- 103
- 104
- 105
- 106
- 107
- 108
- 109
- 110
- 111
- 112
- »